Reviewing Pharmacovigilance Strategies Using Real-World Data for Drug Safety Monitoring and Management

Damilola Oluyemi Merotiwon [1]*, Opeoluwa Oluwanifemi Akomolafe [2], Augustine Onyeka Okoli [3], Erica Afrihyia [4]
[1] Department of Healthcare Administration, University of the Potomac, Washington. D.C. USA.
[2] Independent Researcher, UK
[3] Longmed Medical Centre, Pietermaritzburg, South Africa
[4] Independent Researcher, Ohio, USA

* Corresponding Author: **Damilola Oluyemi Merotiwon**

Article Info

ISSN (online): 3049-0421
Volume: 02
Issue: 03
May-June 2025
Received: 11-03-2025
Accepted: 10-04-2025
Page No: 12-17

Abstract
Pharmacovigilance plays a critical role in ensuring drug safety and protecting public health by identifying, assessing, and mitigating adverse drug reactions (ADRs). The integration of real-world data (RWD) from sources such as electronic health records, patient registries, and social media has significantly enhanced pharmacovigilance strategies, addressing limitations of traditional methods. This paper reviews the framework of pharmacovigilance systems, emphasizing the integration of innovative tools like artificial intelligence (AI), machine learning (ML), and predictive analytics for improved signal detection and proactive risk management. Additionally, advancements in real-time monitoring systems and global collaborations have strengthened drug safety efforts, although challenges related to data quality, privacy, and resource disparities remain significant. Recommendations for improving pharmacovigilance strategies include standardizing data, enhancing stakeholder capacity, and addressing ethical concerns to fully harness the potential of RWD. Future research and policy directions focus on advancing technologies and fostering international cooperation to create a robust and equitable pharmacovigilance ecosystem capable of adapting to evolving healthcare needs.

DOI: https://doi.org/10.54660/IJPGRR.2025.2.3.12-17

Keywords: Pharmacovigilance, Artificial intelligence, Adverse drug reactions, Signal detection, Drug safety monitoring

1. Introduction

Pharmacovigilance, the science of detecting, assessing, and preventing adverse effects or other drug-related problems, is a cornerstone of public health. It ensures pharmaceuticals' continued safety and efficacy throughout their lifecycle, from clinical trials to widespread post-market use (Sadaf & Sameer, 2023). Despite rigorous testing during the pre-approval phase, certain risks associated with drugs often emerge only after extensive real-world exposure (Hodel *et al*., 2024). This is because clinical trials, while thorough, are limited in scale, duration, and the diversity of patient populations. Hence, pharmacovigilance serves as an essential mechanism to monitor, manage, and mitigate these risks, safeguarding public health (Palatty, Sacheendran, & Jayachandran, 2024).

The integration of real-world data (RWD) into pharmacovigilance strategies has revolutionized drug safety monitoring. Derived from various non-experimental sources such as electronic health records (EHRs), insurance claims, and patient registries, RWD offers a wealth of information reflecting actual drug usage and outcomes across diverse populations (Zou, Salem, & Ray, 2022). Unlike data from controlled trials, RWD captures the complexity of real-world clinical settings, making it invaluable for identifying adverse drug reactions (ADRs) and improving overall pharmacovigilance practices. Its utilization enables regulators, researchers, and healthcare providers to detect signals of harm earlier, assess long-term safety profiles, and optimize therapeutic interventions more effectively (Wang *et al*., 2021).

This paper aims to review pharmacovigilance strategies in the context of RWD, exploring its transformative role in enhancing drug safety monitoring. The discussion will outline the pharmacovigilance framework, highlight the role and benefits of RWD, examine innovations in drug safety monitoring, and conclude with recommendations for strengthening pharmacovigilance systems. Through this review, the objective is to underscore how the strategic use of RWD can address existing challenges and advance the field of pharmacovigilance to better protect patients worldwide.

2. Framework for Pharmacovigilance

2.1 Key Components of Pharmacovigilance Systems

Pharmacovigilance systems rely on several foundational elements that enable drug safety monitoring across all stages of the product lifecycle. One primary component is adverse event reporting, where healthcare providers, patients, and pharmaceutical companies contribute data on suspected drug-related issues. These reports form the basis for signal detection, which involves identifying patterns or trends that may indicate previously unknown risks. This process often uses sophisticated algorithms and statistical tools to sift through large datasets (Lucas *et al*., 2022).

Another critical element is risk management, which encompasses both preemptive and responsive measures. Risk evaluation and mitigation strategies (REMS) may be developed to minimize potential harm, especially for drugs with known safety concerns. REMS programs often include education for healthcare providers and patients, distribution restrictions, and regular monitoring of patient outcomes (Dharmani *et al*., 2022).Additionally, pharmacovigilance systems engage in periodic benefit-risk assessment to ensure that the therapeutic value of a drug outweighs its potential risks. This involves generating detailed safety update reports that synthesize findings from various sources, including spontaneous reports, observational studies, and clinical trials. The regulatory oversight and continuous updating of drug labels based on these assessments further ensure patient safety (Piccirillo & Parish, 2022).

2.2 Integration of Traditional Methods with Innovative Tools

Historically, pharmacovigilance relied heavily on spontaneous reporting systems (SRS) and manual analysis of data, which, while effective to a degree, faced challenges like underreporting and delays in detecting safety signals. Today, technological advancements have expanded the capabilities of pharmacovigilance, enabling it to transcend traditional methods.Digital health technologies, such as EHRs and wearable devices, now provide continuous real-time information streams. This shift has improved the quality and timeliness of data collection, reducing the reliance on retrospective reporting. For instance, EHRs link prescription data with clinical outcomes, enabling a more comprehensive understanding of drug effects (Abernethy *et al*., 2022).

Furthermore, artificial intelligence (AI) and machine learning (ML) algorithms have transformed signal detection and risk assessment processes. These tools can analyze vast datasets at unprecedented speeds, uncovering subtle patterns that may escape traditional methods. Powered by AI, predictive analytics helps anticipate potential safety concerns before they escalate into widespread public health issues (Sarker, 2023).

Social media and online patient communities have also emerged as valuable sources of information. Patients frequently share their experiences with medications on these platforms, providing unfiltered insights into potential ADRs. Natural language processing tools are now being used to analyze this data, uncovering real-world patterns and expanding the scope of pharmacovigilance beyond clinical settings (Goel, Goel, & Kumar, 2023).

2.3 Role of Stakeholders in Pharmacovigilance

The effectiveness of any pharmacovigilance system depends on the active participation of various stakeholders, each of whom plays a unique and complementary role in ensuring drug safety.Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are central to pharmacovigilance efforts. These bodies establish guidelines for ADR reporting, conduct post-market surveillance, and enforce compliance with safety regulations. They also review periodic safety update reports (PSURs) and oversee REMS programs to manage identified risks effectively (Chatzopoulou, Eriksson, & Eriksson, 2020).

Healthcare professionals, including physicians, pharmacists, and nurses, are frontline contributors to pharmacovigilance systems. Their role in identifying, reporting, and managing ADRs is indispensable, as they often observe drug-related issues in clinical practice. Their active participation in continuing medical education programs ensures that they remain informed about evolving pharmacovigilance practices (Mofid, Bolislis, & Kühler, 2022).

Patients, too, have become increasingly significant stakeholders, particularly with the rise of patient-reported outcomes and direct consumer reporting systems. Many regulatory agencies have established portals for patients to report ADRs directly, empowering them to contribute firsthand experiences to the safety database. Educating patients about reporting drug-related issues fosters a culture of shared responsibility in pharmacovigilance (Schmidt *et al*., 2021).

Pharmaceutical companies are another crucial group, as they are legally obligated to monitor the safety of their products. They must conduct post-marketing surveillance studies, maintain comprehensive pharmacovigilance systems, and promptly report safety concerns to regulatory authorities. Collaboration between companies and regulators is essential for ensuring a unified approach to drug safety (Tapkir *et al*., 2021).Finally, academic and research institutions contribute by conducting independent studies and advancing methodologies in pharmacovigilance. Their work often provides critical insights into drugs' long-term safety and effectiveness, complementing industry-led efforts (Nwokike, 2023).

3. Role of Real-World Data in Pharmacovigilance

3.1 Sources of Real-World Data

RWD is collected from a variety of sources that reflect the real-world experiences of patients and healthcare systems. One prominent source is electronic health records (EHRs), which store comprehensive patient data, including demographics, diagnoses, treatments, and outcomes. EHRs offer a rich repository for identifying adverse drug reactions (ADRs) and understanding long-term drug safety profiles (Kataria & Ravindran, 2022).

Patient registries are another valuable source. These organized systems collect standardized data about individuals

with specific diseases or conditions, often tracking their treatment journeys over extended periods. Registries provide longitudinal data, making them particularly useful for assessing drug safety in niche or high-risk populations (Liu *et al*., 2022).Administrative claims databases, which include billing and insurance information, are also widely utilized. These datasets allow for large-scale analysis of prescription patterns, hospitalizations, and healthcare resource utilization, offering indirect insights into potential drug-related safety concerns (Xu *et al*., 2023).

Social media and online patient communities have emerged as unconventional but increasingly important sources of RWD. Patients frequently share their medication experiences on platforms like Twitter, Facebook, or specialized forums. When analyzed using natural language processing tools, this information can uncover previously unreported ADRs and provide a broader understanding of patient experiences (Kataria & Ravindran, 2022).

Other sources include wearable devices, mobile health apps, and pharmacovigilance systems dedicated to consumer-reported data. Wearables, for instance, capture real-time physiological data, such as heart rate or blood pressure, which can help identify subtle adverse events associated with medication use. These diverse sources collectively enrich the scope of RWD, making it an indispensable component of modern pharmacovigilance (Phatak, Wieland, Vempala, Volkmar, & Memmert, 2021). Moreover, studies such as Iffat *et al*. (2025) emphasize the importance of public engagement and awareness in enhancing adverse drug reaction reporting systems, highlighting how real-world feedback from patients can significantly strengthen pharmacovigilance infrastructure.

3.2 Advantages of RWD Over Clinical Trial Data in Post-Market Surveillance

While clinical trials are essential for assessing the safety and efficacy of drugs before approval, they have inherent limitations. Trials are typically conducted under controlled conditions with strict inclusion and exclusion criteria. This restricts the diversity of participants and may not fully represent the complexities of real-world clinical settings. RWD, by contrast, captures the experiences of a broader, more heterogeneous patient population, including those with comorbidities, polypharmacy, or demographic variations that are often excluded from trials (Cioeta, Cossu, Giovagnoni, Rigoni, & Muti, 2022).

Another advantage of RWD is its ability to provide insights into the long-term safety and effectiveness of drugs. Clinical trials are generally limited in duration, which can prevent the identification of delayed adverse effects. Post-market surveillance using RWD helps bridge this gap by enabling continuous monitoring of drugs over time. This is particularly crucial for identifying rare or cumulative ADRs that might only emerge after widespread use (Dagenais, Russo, Madsen, Webster, & Becnel, 2022).

RWD also facilitates the study of drug safety in specific subpopulations, such as pregnant women, elderly patients, or those with rare conditions, who are often underrepresented in clinical trials. This targeted analysis enhances the precision of pharmacovigilance efforts and informs tailored risk management strategies (Bérard, 2021).The large scale and granularity of RWD allow for more robust signal detection. By leveraging data from millions of real-world cases, pharmacovigilance systems can identify patterns and associations with greater statistical power. Furthermore, RWD supports proactive risk assessment by enabling predictive analytics, helping to identify potential safety concerns before they escalate into significant public health issues (Yang, 2021).

3.3 Challenges in Leveraging RWD

Despite its numerous advantages, the use of RWD in pharmacovigilance is not without challenges. One of the primary concerns is data quality. RWD is often collected for purposes other than research, such as billing or clinical documentation, which can result in incomplete, inconsistent, or inaccurate records. Addressing these issues requires rigorous data cleaning, validation, and standardization processes (Segun-Falade *et al*., 2024).Another significant challenge is data privacy. RWD frequently contains sensitive personal information, raising concerns about confidentiality and compliance with data protection regulations like the General Data Protection Regulation (GDPR). Ensuring the ethical use of RWD involves implementing robust anonymization techniques and secure data-sharing protocols (Bérard, 2021).

The fragmented nature of RWD sources also poses difficulties. Data from EHRs, registries, and claims systems often reside in siloed formats, making integrating and harmonizing information across platforms challenging. Interoperability standards and collaborative frameworks are needed to overcome this barrier and enable seamless data exchange.

Moreover, biases inherent in RWD can affect the reliability of findings. For example, data from social media may overrepresent certain demographics, while claims data might not account for out-of-pocket drug purchases. Advanced analytical methods and careful study design are essential to mitigate these biases and ensure the validity of RWD-based insights.Finally, there are technical and resource-related challenges. Leveraging RWD requires significant investments in infrastructure, expertise, and computational tools. Not all healthcare systems or regulatory bodies have the capacity to fully harness the potential of RWD, creating disparities in pharmacovigilance capabilities across regions (Zisis, Pavi, Geitona, & Athanasakis, 2023).

4. Advancements and Innovations in Drug Safety Monitoring

4.1 Use of Artificial Intelligence and Machine Learning in Signal Detection

The advent of AI and ML has revolutionized signal detection, which is a critical aspect of pharmacovigilance. Traditional methods of identifying potential safety concerns relied heavily on manual review and basic statistical techniques, often making the process time-consuming and prone to oversight. AI-driven tools, however, have introduced unprecedented efficiency and accuracy by automating the analysis of large, complex datasets (Johnson, Olamijuwon, Cadet, Osundare, & Ekpobimi).

For example, ML algorithms can rapidly analyze spontaneous reporting system databases, EHRs, and other real-world data sources to identify patterns and correlations indicative of potential ADRs. These algorithms are capable of recognizing subtle signals that may not be immediately apparent through conventional methods, such as rare or delayed-onset adverse events. Natural language processing (NLP), a subset of AI, further enhances signal detection by

analyzing unstructured data, including clinical notes, social media posts, and patient forums, for evidence of drug-related issues.

In addition to detecting signals more quickly, AI and ML improve the precision of pharmacovigilance efforts by reducing false-positive rates. By continuously learning from new data, these systems refine their predictive models, leading to more accurate identification of true safety concerns. Regulatory agencies and pharmaceutical companies have increasingly adopted these technologies to enhance their pharmacovigilance capabilities, ensuring that potential risks are flagged and addressed more efficiently (Ehidiamen & Oladapo, 2024d; M. C. Kelvin-Agwu, M. O. Adelodun, G. T. Igwama, & E. C. Anyanwu, 2024).

4.2 Predictive Analytics for Adverse Event Identification

Predictive analytics has emerged as a powerful tool in the proactive management of drug safety. By leveraging historical data and advanced statistical models, predictive analytics enables stakeholders to anticipate the likelihood of specific ADRs before they occur. This approach shifts the focus of pharmacovigilance from reactive to preventive, reducing the burden of managing widespread safety concerns after they arise.

One key application of predictive analytics is in identifying at-risk populations. By analyzing patient characteristics, such as age, comorbidities, and concurrent medications, predictive models can estimate the probability of adverse reactions in specific groups. This information is invaluable for tailoring risk management strategies and informing clinical decision-making (Shittu, Ehidiamen, Ojo, & Christophe, 2024).

Predictive analytics is also instrumental in optimizing drug development and post-marketing surveillance. During the development phase, predictive models help identify potential safety issues early, guiding adjustments to study designs or dosing regimens. Post-approval, these tools facilitate the monitoring of drug performance in real-world settings, highlighting trends that may require further investigation or regulatory action.

Moreover, predictive analytics supports the assessment of benefit-risk profiles by quantifying the likelihood and impact of ADRs relative to therapeutic benefits. This helps ensure that patients derive maximum value from medications while minimizing potential harm. The integration of predictive analytics into pharmacovigilance workflows is a testament to its transformative potential in enhancing drug safety (Ehidiamen & Oladapo, 2024c; Mbunge *et al*., 2024).

4.3 Real-Time Monitoring Systems and Global Collaborations

Real-time monitoring systems have emerged as a cornerstone of modern pharmacovigilance, enabling continuous surveillance of drug safety across diverse settings. These systems utilize dynamic data streams from sources such as wearable devices, mobile health applications, and interconnected EHR networks. By providing near-instantaneous feedback, real-time monitoring enhances signal detection and response timeliness (Ehidiamen & Oladapo, 2024a).

Wearable devices, for instance, capture physiological parameters like heart rate, blood pressure, and glucose levels in real-time, offering valuable insights into the immediate effects of medications. Similarly, mobile health apps allow patients to report symptoms or side effects directly, creating an ongoing flow of actionable data. These innovations empower healthcare providers and regulatory agencies to promptly identify and address safety concerns.

Global collaborations further amplify the impact of real-time monitoring systems. Initiatives such as the International Council for Harmonisation (ICH) and the World Health Organization (WHO) Program for International Drug Monitoring have established frameworks for sharing pharmacovigilance data across borders. This global exchange of information enhances the detection of rare ADRs that may only become evident through large, multinational datasets (Ehidiamen & Oladapo, 2024b; M. Kelvin-Agwu, M. O. Adelodun, G. T. Igwama, & E. C. Anyanwu, 2024).

The establishment of global databases, such as VigiBase managed by the WHO, has facilitated the aggregation and analysis of ADR reports from member countries. These platforms enable regulators and researchers to detect safety signals that may not be apparent in individual regions due to limited case numbers. Collaborative efforts also promote harmonization of pharmacovigilance practices, ensuring consistent standards for drug safety monitoring worldwide.

In addition to regulatory collaborations, partnerships between academia, industry, and technology providers have driven innovation in pharmacovigilance. Joint research initiatives and pilot projects have explored the application of emerging technologies in drug safety monitoring, advancing the field as a whole (Adelodun & Anyanwu; M. Kelvin-Agwu *et al*., 2024).

5. Conclusion

RWD plays an essential role in post-market surveillance, addressing the limitations of clinical trials by offering insights into drug performance across diverse populations and in real-world settings. The use of AI and predictive analytics has significantly improved the timeliness and accuracy of signal detection, enabling stakeholders to proactively identify safety risks. Real-time monitoring systems and global collaborations have further strengthened pharmacovigilance efforts, creating opportunities for swift action and harmonization of practices worldwide.Despite these advancements, the challenges of utilizing RWD, including fragmented data sources, privacy concerns, and potential biases, remain critical barriers. These issues require targeted solutions to fully leverage the potential of RWD in improving drug safety.

To maximize the benefits of RWD, it is crucial to prioritize data standardization and interoperability. Harmonizing data formats and establishing unified data-sharing frameworks can help overcome fragmentation, enabling more comprehensive analyses. Regulatory agencies and industry stakeholders should invest in infrastructure and tools to integrate RWD sources seamlessly, such as EHRs, registries, and wearable devices.

Enhancing data quality through robust validation processes is equally important. Implementing stringent data collection, cleaning, and curation protocols can ensure that insights derived from RWD are reliable and actionable. Furthermore, addressing privacy concerns through advanced anonymization techniques and secure data-sharing platforms is essential for maintaining public trust and complying with regulatory requirements.

Building capacity among stakeholders is another critical recommendation. Training healthcare providers, regulators, and industry professionals to effectively use RWD tools and

technologies can improve their ability to identify and manage safety risks. Public awareness campaigns encouraging patient participation in ADR reporting systems can further enrich the quality and scope of pharmacovigilance data.

6. References

1. Abernethy A, Adams L, Barrett M, Bechtel C, Brennan P, Butte A, *et al*. The promise of digital health: then, now, and the future. NAM perspectives. 2022.
2. Adelodun MO, Anyanwu EC. Global Standards in Radiation Safety: A Comparative Analysis of Healthcare Regulations.
3. Bérard A. Pharmacoepidemiology research-real-world evidence for decision making. Frontiers Media SA. 2021;12:723427.
4. Chatzopoulou S, Eriksson NL, Eriksson D. Improving risk assessment in the European food safety authority: lessons from the European Medicines Agency. Frontiers in Plant Science. 2020;11:349.
5. Cioeta R, Cossu A, Giovagnoni E, Rigoni M, Muti P. A new platform for post-marketing surveillance and real-world evidence data collection for substance-based medical devices. Frontiers in Drug Safety and Regulation. 2022;2:992359.
6. Dagenais S, Russo L, Madsen A, Webster J, Becnel L. Use of real-world evidence to drive drug development strategy and inform clinical trial design. Clinical Pharmacology & Therapeutics. 2022;111(1):77-89.
7. Dharmani C, Wang E, Salas M, McCabe C, Diggs A, Choi Y, *et al*. Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience. Future Oncology. 2022;18(13):1595-1607.
8. Ehidiamen AJ, Oladapo OO. Innovative approaches to risk management in clinical research: Balancing ethical standards, regulatory compliance, and intellectual property concerns. World Journal of Biology Pharmacy and Health Sciences. 2024;20(1):349-363. Available from: https://doi.org/10.30574/wjbphs.2024.20.1.0791
9. Ehidiamen AJ, Oladapo OO. The intersection of clinical trial management and patient advocacy: How research professionals can promote patient rights while upholding clinical excellence. 2024.
10. Ehidiamen AJ, Oladapo OO. Optimizing contract negotiations in clinical research: Legal strategies for safeguarding sponsors, vendors, and institutions in complex trial environments. World Journal of Biology Pharmacy and Health Sciences. 2024;20(1):335-348. Available from: https://doi.org/10.30574/wjbphs.2024.20.1.0790
11. Ehidiamen AJ, Oladapo OO. The role of electronic data capture systems in clinical trials: Streamlining data integrity and improving compliance with FDA and ICH/GCP guidelines. 2024.
12. Goel A, Goel AK, Kumar A. The role of artificial neural network and machine learning in utilizing spatial information. Spatial Information Research. 2023;31(3):275-285.
13. Hodel KVS, Fiuza BSD, Conceição RS, Aleluia ACM, Pitanga TN, Fonseca LMdS, *et al*. Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review. Pharmaceuticals. 2024;17(6):807.
14. Iffat W, Shakeel S, Nesar S, Qamar A, Huma Z, Rehman H, *et al*. Assessment of public awareness and perspectives towards adverse drug reaction reporting system in Karachi, Pakistan. PLOS ONE. 2025;20(2):e0318139. doi: 10.1371/journal.pone.0318139
15. Johnson OB, Olamijuwon J, Cadet E, Osundare OS, Ekpobimi HO. Optimizing Predictive Trade Models through Advanced Algorithm Development for Cost-Efficient Infrastructure.
16. Kataria S, Ravindran V. Harnessing of real-world data and real-world evidence using digital tools: utility and potential models in rheumatology practice. Rheumatology. 2022;61(2):502-513.
17. Kelvin-Agwu M, Adelodun MO, Igwama GT, Anyanwu EC. The Impact of Regular Maintenance on the Longevity and Performance of Radiology Equipment. 2024.
18. Kelvin-Agwu MC, Adelodun MO, Igwama GT, Anyanwu EC. Strategies For Optimizing The Management Of Medical Equipment In Large Healthcare Institutions. Strategies. 2024;20(9):162-170.
19. Liu J, Barrett JS, Leonardi ET, Lee L, Roychoudhury S, Chen Y, *et al*. Natural history and real-world data in rare diseases: applications, limitations, and future perspectives. The Journal of Clinical Pharmacology. 2022;62:S38-S55.
20. Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: reporting requirements throughout a product's lifecycle. Therapeutic advances in drug safety. 2022;13:20420986221125006.
21. Mbunge E, Fashoto SG, Akinnuwesi BA, Metfula AS, Manyatsi JS, Sanni SA, *et al*. Machine Learning Approaches for Predicting Individual's Financial Inclusion Status with Imbalanced Dataset. Computer Science On-line Conference. 2024.
22. Mofid S, Bolislis WR, Kühler TC. Real-world data in the postapproval setting as applied by the EMA and the US FDA. Clinical Therapeutics. 2022;44(2):306-322.
23. Nwokike J. Regulatory reliance and post-marketing surveillance systems for safe and accelerated introduction of new medical products in low-and middle-income countries [dissertation]. University of Plymouth; 2023.
24. Palatty PL, Sacheendran D, Jayachandran M. Mitigating Challenges in Pharmacovigilance. 2024.
25. Phatak AA, Wieland FG, Vempala K, Volkmar F, Memmert D. Artificial intelligence based body sensor network framework—narrative review: proposing an end-to-end framework using wearable sensors, real-time location systems and artificial intelligence/machine learning algorithms for data collection, data mining and knowledge discovery in sports and healthcare. Sports Medicine-Open. 2021;7(1):79.
26. Piccirillo RA, Parish J. Pharmacovigilance principles: the building blocks of benefit-risk assessments. Glob Clin Transl Res. 2022;4(4):1-7.
27. Sadaf DS, Sameer S. Pharmacovigilance and adverse event detection: a comprehensive review of artificial intelligence applications. European Journal of Modern Medicine and Practice. 2023;3(12):97-104.
28. Sarker IH. Machine learning for intelligent data analysis and automation in cybersecurity: current and future prospects. Annals of Data Science. 2023;10(6):1473-1498.

29. Schmidt T, Valuck T, Perkins B, Riposo J, Patel P, Westrich K, *et al*. Improving patient-reported measures in oncology: a payer call to action. Journal of Managed Care & Specialty Pharmacy. 2021;27(1):118-126.
30. Segun-Falade OD, Osundare OS, Kedi WE, Okeleke PA, Ijomah TI, Abdul-Azeez OY. Utilizing machine learning algorithms to enhance predictive analytics in customer behavior studies. 2024.
31. Shittu RA, Ehidiamen AJ, Ojo OO, Christophe SJ. The role of business intelligence tools in improving healthcare patient outcomes and operations. 2024.
32. Tapkir N, Soni F, Sahu AK, Jadav T, Tekade RK, Sengupta P. A comprehensive review on assessment and key control strategies for impurities in drug development with a special emphasis on post-marketing surveillance. Journal of Pharmaceutical Innovation. 2021:1-20.
33. Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, *et al*. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;372.
34. Xu Y, Zheng X, Li Y, Ye X, Cheng H, Wang H, *et al*. Exploring patient medication adherence and data mining methods in clinical big data: A contemporary review. Journal of Evidence-Based Medicine. 2023;16(3):342-375.
35. Yang H. Using real-world evidence to transform drug development: opportunities and challenges. Real-World Evidence in Drug Development and Evaluation. 2021:1-26.
36. Zisis K, Pavi E, Geitona M, Athanasakis K. Real-world data: A systematic literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process. medRxiv. 2023. doi: 2023.2010.2018.23297151
37. Zou KH, Salem LA, Ray A. Real-world evidence in a patient-centric digital era. CRC Press; 2022.